The World Health Organization 2008 descriptions of CML, BCR-ABL1 positive, and chronic neutrophilic leukemia
mention the markedly decreased neutrophil alkaline phosphatase of the chronic phase (CP) neutrophils.
The study conducted by researchers at the Knight Cancer Institute at Oregon Health and Science University (OHSU) isolated the molecular mutation that causes chronic neutrophilic leukemia
(CNL) and atypical chronic myeloid leukemia (aCML) in some patients.
TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
The 2008 WHO classification of MPNs has added new entities, including chronic myelogenous leukemia, Philadelphia chromosome-positive (CML); chronic neutrophilic leukemia
(CNL); polycythemia vera (PV); primary myelofibrosis (PMF); essential thrombocythemia (ET); chronic eosinophilic leukemia, not otherwise specified (CEL/NOS); mastocytosis; and myeloproliferative neoplasm, unclassifiable (MPN-U).
This mutation has also been found in patients with non-classic MPDs such as refractory anemia with ringed sideroblasts associated with thrombocytosis (RARS-T), chronic neutrophilic leukemia
(CNL), atypical chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML) at incidences of 50%, 20%, 20% and 3%, respectively.
The differential diagnosis of CML includes granulocytic leukemoid reactions, chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia
(CNL), and reactive causes of eosinophilia, basophilia, and monocytosis.
Chronic myelogenous leukemia Chronic myelomonocytic leukemia Mast cell leukemia Chronic monocytic leukemia Chronic neutrophilic leukemia
Chronic eosinophilic leukemia